New Jersey § 24:6i-7

§ 24:6i-7.

a. The commission shall issue clinical registrant permits to qualified applicants

that meet the requirements of this section. In addition to any other requirements as the commission establishes by regulation

regarding application for and issuance of a clinical registrant permit, each clinical

registrant applicant shall: (1) complete a criminal history record background check that meets the requirements

of subsection d. of section 7 of P.L.2009, c. 307 ( C.24:6I-7 ); (2) submit to the commission any required application and permit fees; (3) submit to the commission written documentation of an existing contract with an

academic medical center that meets the requirements of subsection c. of this section;

and (4) submit to the commission documentation that the applicant has a minimum of $15

million in capital. b. The commission shall, no later than 90 days after the effective date of P.L.2019, c. 153 ( C.24:6I-5.1 et al.) 1 or upon adoption of rules and regulations as provided in subsection c. of section

18 of P.L.2009, c. 307 ( C.24:6I-16 ), whichever occurs first, begin accepting and processing applications for five clinical registrant permits. Thereafter, the commission shall accept applications for and issue such additional

clinical registrant permits as it determines to be necessary and consistent with the

provisions of P.L.2009, c. 307 ( C.24:6I-1 et al.). The commission shall make a determination as to a clinical registrant permit application

no later than 90 days after receiving the application, which may include a determination

that the commission reasonably requires more time to adequately review the application. In reviewing and approving applications for clinical registrant permits, the commission

shall seek to incorporate the policies, practices, protocols, standards, and criteria

developed by the Office of Minority, Disabled Veterans, and Women Cannabis Business Development pursuant to section 32 of P.L.2019, c. 153 ( C.24:6I-25 ) to promote participation in the medical cannabis industry by persons from socially

and economically disadvantaged communities. In no case shall the commission accept, process, or approve an application submitted

by an applicant that has contracted with an academic medical center that is part of

a health care system that includes another academic medical center that has contracted

with an applicant for, or a holder of, a clinical registrant permit. c. A contract between a clinical registrant and an academic medical center shall include

a commitment by the academic medical center, or its affiliate, to engage in or oversee clinical research related to the use or adverse effects of cannabis in order to advise the clinical registrant concerning patient health and

safety, medical applications, dispensing and management of controlled substances, and ways to mitigate adverse health or societal effects of adult, personal use legalization, among other areas. A clinical registrant issued a permit pursuant to this section shall have a written

contractual relationship with no more than one academic medical center. d. A clinical registrant issued a permit pursuant to this section shall be authorized

to engage in all conduct involving the cultivation, manufacturing, and dispensing

of medical cannabis as is authorized for an entity holding medical cannabis cultivator,

medical cannabis manufacturer, and medical cannabis dispensary permits pursuant to P.L.2009, c. 307 ( C.24:6I-1 et al.), including dispensing medical cannabis and medical cannabis products to qualifying

patients and designated and institutional caregivers. The clinical registrant shall additionally be authorized to engage in clinical research

involving medical cannabis using qualifying patients who consent to being part of

such research, subject to any restrictions established by the commission. e. (1) A clinical registrant issued a permit pursuant to this section may conduct

authorized activities related to medical cannabis at more than one physical location,

provided that each location is approved by the commission and is in the same region

in which the academic medical center with which the clinical registrant has a contract

is located. (2) A clinical registrant may apply to the commission for approval to relocate an

approved facility to another location in the same region, which application shall

be approved unless the commission makes a specific determination that the proposed

relocation would be inconsistent with the purposes of P.L.2009, c. 307 ( C.24:6I-1 et al.). The denial of an application for relocation submitted pursuant to this paragraph

shall be considered a final agency decision, subject to review by the Appellate Division

of the Superior Court. (3) The commission may authorize a clinical registrant to dispense medical cannabis

and medical cannabis products from more than one physical location if the commission

determines that authorizing additional dispensing locations is necessary for the clinical

registrant to best serve and treat qualifying patients and clinical trial participants. (4) In no case shall a clinical registrant operate or be located on land that is valued,

assessed or taxed as an agricultural or horticultural use pursuant to the “Farmland

Assessment Act of 1964,” P.L.1964, c. 48 ( C.54:4-23.1 et seq. ). f. A clinical registrant permit shall not be sold or transferred to any other entity. g. Clinical registrant permits shall be valid for the term of the contractual relationship

between the academic medical center and the clinical registrant. The commission may renew a clinical registrant permit to correspond to any renewal

of the contractual relationship between the academic medical center and the clinical

registrant. h. Each clinical registrant shall submit the results of the clinical research obtained

through an approved clinical registrant permit to the commission no later than one

year following the conclusion of the research study or publication of the research

study in a peer-reviewed medical journal. Nothing in this subsection shall be deemed to require the disclosure of any clinical

research that would infringe on the intellectual property of the clinical registrant

or on the confidentiality of patient information. i. Application materials submitted to the commission pursuant to this section shall

not be considered a public record pursuant to P.L.1963, c. 73 ( C.47:1A-1 et seq. ) , P.L.2001, c. 404 ( C.47:1A-5 et al.) , or the common law concerning access to records . 1

L.2019, c. 153, eff. July 2, 2019.